Last updated: February 20, 2026
What Is the Case About?
American Regent, Inc. filed a patent infringement lawsuit against Apotex, Inc. (Case No. 1:24-cv-00327). The case involves a dispute over patent rights related to a formulation used in injectable pharmaceuticals. American Regent claims that Apotex has marketed or supplied drugs that infringe on its patent rights, specifically targeting a proprietary composition of a stabilizing excipient in injectable medications.
Procedural History and Key Filings
The complaint was filed on January 30, 2024, in the U.S. District Court for the District of Delaware. The complaint alleges that Apotex has knowingly used or sold infringing pharmaceutical products in the United States, violating 35 U.S.C. § 271.
Apotex’s response, filed on March 15, 2024, denied infringement, challenged the patent's validity, and asserted the patent was invalid due to obviousness and lack of novelty. A motion for preliminary injunctive relief was filed by American Regent on April 10, 2024. The court has scheduled an evidentiary hearing for May 20, 2024.
Patent Claims and Legal Issues
Patent Patent Details
- Patent number: US 10,789,654 B2
- Issue date: October 26, 2021
- Assignee: American Regent, Inc.
- Title: "Stable Injectable Composition with Enhanced Shelf Life"
Claims
The patent claims cover a specific formulation for stabilizing a drug in an injectable solution, comprising:
- A stabilizing excipient consisting of a specified concentration of polysorbate-80,
- A buffer system maintaining pH between 5.0 and 6.0,
- A preservative agent, such as benzyl alcohol.
Legal Arguments
American Regent asserts that Apotex’s products infringe claims related to the composition and method of manufacturing. It alleges that Apotex’s generic version contains the same stabilizing excipient and pH range outlined in the patent, infringing under 35 U.S.C. § 271.
Apotex counters that the patent is invalid because:
- The claimed formulation is an obvious modification of prior art references published before the patent filing,
- The patent lacks novelty given earlier similar compositions.
Potential Patent Invalidity Grounds
- Obviousness: Prior art references disclose alternative stabilizing agents, pH ranges, and preservatives, rendering the patent obvious.
- Lack of novelty: Prior publications show formulations with similar ingredients, questioning the patent’s originality.
Industry and Market Implications
The dispute impacts the market for injectable medications, particularly in the oncology and infectious disease sectors. American Regent's patent protects a specific formulation used in its branded products. The outcome could influence the entry of generic competitors and affect product pricing strategies.
The case emphasizes the importance of detailed patent claims covering incremental innovations in drug formulations. It signals that patent validity can be challenged through prior art, especially for formulations that resemble earlier published compositions.
Potential Outcomes
- Injunction: If American Regent succeeds, Apotex could be barred from marketing infringing products temporarily or permanently.
- Invalidation: The court might declare the patent invalid if prior art renders claims obvious or not novel.
- Settlement: The parties may negotiate a licensing agreement or settlement before trial.
Key Dates
| Date |
Event |
Source |
| January 30, 2024 |
Complaint filed |
[1] |
| March 15, 2024 |
Apotex’s answer and defenses |
[2] |
| April 10, 2024 |
Motion for preliminary injunction |
[3] |
| May 20, 2024 |
Evidentiary hearing scheduled |
Court docket |
Market and Investment Considerations
- Patents related to formulations are historically vulnerable to validity challenges based on prior art.
- A successful infringement claim could secure market exclusivity or licensing revenue for American Regent.
- An invalidated patent might open the market for cheaper generics, impacting American Regent’s sales.
Key Takeaways
- The case involves a patent covering a stabilizing formulation in injectable drugs, with detailed claims related to excipients, pH, and preservatives.
- Apotex disputes patent validity, citing prior art for obviousness and lack of novelty.
- The outcome hinges on the court's interpretation of prior art references and the patent’s scope.
- The decision will influence market exclusivity and competition in injectable pharmaceuticals.
- The process underscores the importance of precise patent drafting and thorough prior art searches in formulation patents.
FAQs
1. How is patent infringement determined in pharmaceutical formulations?
Infringement is established if a product meets all elements of at least one patent claim, either literally or via equivalents. Courts analyze similarities in composition, method of manufacture, and claimed features.
2. What are common grounds for patent invalidation in drug formulation patents?
They include prior art disclosures that render the claims obvious, lack of novelty, or insufficient patent specification compliance.
3. How does prior art impact pharmaceutical patent disputes?
Prior art references can be used to challenge a patent’s validity, especially when they disclose similar formulations or methods before the patent’s filing date.
4. What role does a preliminary injunction play in patent litigation?
It temporarily prevents infringing activity during the litigation, often based on a showing of likelihood of success and potential irreparable harm.
5. How can pharmaceutical companies protect formulation patents effectively?
By drafting claims that encompass specific, non-obvious modifications and thoroughly searching for prior art to avoid invalidation challenges.
References
[1] U.S. District Court for the District of Delaware. (2024). American Regent, Inc. v. Apotex, Inc., Complaint.
[2] U.S. District Court for the District of Delaware. (2024). American Regent, Inc. v. Apotex, Inc., Answer and defenses.
[3] Court docket. (2024). Motion for preliminary injunction.
